Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
18 studies found for:    "Indolent B cell lymphoma"
Show Display Options
Download search resultsDownload the search results for:
"Indolent B cell lymphoma" (18 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Conditions: B-cell Lymphoma;   Indolent B-cell Lymphoma
Intervention: Drug: rituximab
2 Recruiting A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Conditions: Indolent B-cell Lymphoma;   Chronic Lymphocytic Leukaemia
Intervention: Drug: DI-B4
3 Active, not recruiting Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
Intervention: Drug: ofatumumab
4 Recruiting Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies
5 Completed VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Lymphoma
Intervention: Drug: VELCADE and rituximab
6 Withdrawn Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, B-Cell, Marginal Zone;   Lymphoma, Low-Grade;   Lymphoma, Intermediate-Grade
Intervention: Drug: Ofatumumab
7 Completed
Has Results
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Conditions: Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
8 Active, not recruiting Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Romidepsin
9 Recruiting Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
10 Terminated A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell
Intervention: Drug: AEG35156 antisense IV infusion
11 Unknown  Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine;   Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
12 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
13 Completed Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Drug: bortezomib + rituximab
14 Unknown  Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: rituximab;   Biological: sargramostim
15 Completed Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: keyhole limpet hemocyanin;   Biological: sargramostim;   Biological: tumor cell-based vaccine therapy
16 Completed Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide;   Biological: aldesleukin;   Genetic: polymerase chain reaction;   Genetic: gene rearrangement analysis;   Procedure: lymph node biopsy;   Biological: genetically engineered lymphocyte therapy;   Procedure: bone marrow aspiration;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay
17 Withdrawn Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Condition: Lymphoma
Interventions: Biological: recombinant interferon alfa;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
18 Unknown  Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
Conditions: Immunocytoma/Morbus Waldenström;   B-Cell Non-Hodgkin's Lymphoma;   B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Cyclophosphamide, Pentostatin, Rituximab

Indicates status has not been verified in more than two years